Antibody and Complement Levels in Patients with Hypersplenism Associated with Cirrhotic Portal Hypertension and Therapeutic Principles

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2023 Jan 23

PMID 36683645

Authors

Kun Zhang

Min Zeng

Ye-Juan Li

Hong-Fei Wu

Jin-Cai Wu

Zhen-Sheng Zhang

Jin-Fang Zheng

Yun-Fu Lv

Affiliations

Soon will be listed here.

Abstract

Background: Hypersplenism associated with cirrhotic portal hypertension is a common condition often resulting from hepatitis B-related cirrhosis. However, the levels of immunoglobulin (Ig) and complement in patients with hypersplenism associated with cirrhotic portal hypertension remain unclear. This study was undertaken to determine the levels of Ig and complement in these patients, the relationship between these levels and Child-Pugh class and their clinical significance.

Aim: To investigate the antibody (Ig) and complement levels in patients with hypersplenism associated with cirrhotic portal hypertension and their clinical significance.

Methods: Clinical data of 119 patients with hypersplenism associated with cirrhotic portal hypertension were statistically analyzed and compared with those of 128 control patients.

Results: IgA and IgG levels in patients with hypersplenism were significantly higher than controls ( < 0.001). There was no significant difference in IgM between the two groups ( = 0.109). C3 and C4 levels in patients with hypersplenism were significantly lower than controls ( < 0.001). As liver function decreased, IgA and IgG levels increased ( < 0.001), and C3 and C4 levels decreased ( < 0.001).

Conclusion: Patients with hypersplenism associated with cirrhotic portal hypertension have significantly higher antibody (IgA and IgG) levels and significantly lower complement (C3 and C4) levels, which are both related to liver damage. Clinically, the administration of anti-hepatitis virus agents and protection of liver function should be strengthened.

Citing Articles

Thyroid hormone, immunoglobin and complements for predicting hepatocellular carcinoma development in patients with hepatitis B virus-related liver cirrhosis.

Tong X, Liu K, Huang Z, Zhang X, Xue Y World J Hepatol. 2025; 17(2):99092.

PMID: 40027558 PMC: 11866162. DOI: 10.4254/wjh.v17.i2.99092.

References

Antunes J, Kochuyt A, Ceuppens J . Perioperative allergic reactions: experience in a Flemish referral centre. Allergol Immunopathol (Madr). 2013; 42(4):348-54. DOI: 10.1016/j.aller.2013.08.001. View

Hadge D . [Evolution of the immunoglobulins]. Allerg Immunol (Leipz). 1985; 31(4):231-43. View

Lin S, Sun Q, Mao W, Chen Y . Serum Immunoglobulin A (IgA) Level Is a Potential Biomarker Indicating Cirrhosis during Chronic Hepatitis B Infection. Gastroenterol Res Pract. 2016; 2016:2495073. PMC: 4829706. DOI: 10.1155/2016/2495073. View

Kennedy M, Alexopoulos S . Hepatitis B virus infection and liver transplantation. Curr Opin Organ Transplant. 2010; 15(3):310-5. DOI: 10.1097/MOT.0b013e32833991f8. View

Duriez M, Mandouri Y, Lekbaby B, Wang H, Schnuriger A, Redelsperger F . Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity. J Hepatol. 2017; 67(4):687-699. PMC: 6433284. DOI: 10.1016/j.jhep.2017.05.025. View

Yang X, Sun J, Gao Y, Tan A, Zhang H, Hu Y . Genome-wide association study for serum complement C3 and C4 levels in healthy Chinese subjects. PLoS Genet. 2012; 8(9):e1002916. PMC: 3441730. DOI: 10.1371/journal.pgen.1002916. View

Liu A, Jena P, Wysocki L . Tracing the development of single memory-lineage B cells in a highly defined immune response. J Exp Med. 1996; 183(5):2053-63. PMC: 2192589. DOI: 10.1084/jem.183.5.2053. View

Zhang Q, Gao Y, Peng Y, Fu M, Liu Y, Zhou Q . Epidemiological survey of human cytomegalovirus antibody levels in children from Southeastern China. Virol J. 2014; 11:123. PMC: 4094890. DOI: 10.1186/1743-422X-11-123. View

Rouse B . Virus-induced immunopathology. Adv Virus Res. 1996; 47:353-76. PMC: 7130923. DOI: 10.1016/s0065-3527(08)60739-3. View

10.

DAMESHEK W . Hypersplenism. Bull N Y Acad Med. 1955; 31(2):113-36. PMC: 1804426. View

11.

Baig S, Alamgir M . The extrahepatic manifestations of hepatitis B virus. J Coll Physicians Surg Pak. 2008; 18(7):451-7. DOI: 07.2008/JCPSP.451457. View

12.

Watt K, Uhanova J, Gong Y, Kaita K, Doucette K, Pettigrew N . Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection. J Viral Hepat. 2004; 11(3):251-6. DOI: 10.1111/j.1365-2893.2004.00507.x. View

13.

Loh R, Vale S, McLean-Tooke A . Quantitative serum immunoglobulin tests. Aust Fam Physician. 2013; 42(4):195-8. View

14.

Chang W, Chuang W . Complements as new diagnostic tools of hepatocellular carcinoma in cirrhotic patients. Cancer. 1988; 62(2):227-32. DOI: 10.1002/1097-0142(19880715)62:2<227::aid-cncr2820620202>3.0.co;2-d. View

15.

Feizi T . Immunoglobulins in chronic liver disease. Gut. 1968; 9(2):193-8. PMC: 1552579. DOI: 10.1136/gut.9.2.193. View

16.

Lv Y, Gong X, Xie X, Wang B, Yang Y, Li Y . Clinical study on the relationship between hematocytopenia and splenomegaly caused by cirrhotic portal hypertension. Cell Biochem Biophys. 2014; 70(1):355-60. DOI: 10.1007/s12013-014-9920-9. View

17.

Vaerman J . [Effector mechanisms of IgA]. Ann Biol Clin (Paris). 1984; 42(1):61-70. View

18.

Lei Z, Xia Y, Si A, Wang K, Li J, Yan Z . Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection. J Hepatol. 2017; 68(4):655-662. DOI: 10.1016/j.jhep.2017.11.015. View

19.

Ortarik Z, Toyran A, Sen S, Mart Komurcu S, Guvener E . [Evaluation of serum IgG, IgA and IgM levels as indicators of hepatic fibrosis in patients with chronic hepatitis C infection]. Mikrobiyol Bul. 2011; 45(2):296-305. View

20.

Gonzalez-Quintela A, Alende M, Gamallo R, Gonzalez-Gil P, Lopez-Ben S, Tome S . Serum immunoglobulins (IgG, IgA, IgM) in chronic hepatitis C. A comparison with non-cirrhotic alcoholic liver disease. Hepatogastroenterology. 2003; 50(54):2121-6. View